Start here — using TopoMT Discussions #132

Work tracking — 2026-11-08

Concrete follow-up described here is routed to #153. The issue board owns scheduling and disposition; the action map identifies the scope. A reply or deferred study question must not become an invisible work queue.

Keep scientific analysis and dated history in this conversation. Before treating an old result as a current limitation, read the latest linked issue/finding disposition and its software profile.

Welcome to TopoMT Discussions. This is a place to ask questions, study methods and scientific resources, compare evidence and discuss how molecular topography should be characterized.

Where to start

• Q&A: using TopoMT, interpreting results and navigating its public API.
• Ideas: exploratory scientific, algorithmic and user-workflow questions.
• Methods and Tools: algorithms, programs, libraries and services. Start with the resource index #68.
• Datasets and Benchmarks: collections, independent references, metrics, protocols and comparative results. Start with the dataset index #92.
• Literature and Resources: primary papers, critical reading, findings and open questions. Start with the reading index.
• Announcements: maintainer updates and links to recorded milestones.

Search before opening a conversation; reuse one canonical thread per resource across versions. A name, official source and reason for interest are enough to propose a resource. Unknown technical details are welcome.

Labels describe the subject: feature: for topographic phenomena, context: for synthetic/molecular/trajectory questions, role: for the relationship to TopoMT, and topic: for central DFND/API/performance questions. They are independent facets, not validation certificates.

Our current scientific direction

Develop DFND one independently referenced synthetic case at a time, then proceed to new protein characterization. Discuss method definitions and comparison questions openly. Reproducible inputs and results live in the versioned system studies, linked from the relevant conversations; study cases have descriptive names without catalogue numbering.

Keep reviews, arguments, evidence and conclusions in Discussions. Actionable suspected bugs, missing capabilities and bounded implementation/validation work belong in owning issues, linked both ways. Preserve the distinction between source-reported claims, our interpretations and reproduced observations. Catalogue membership does not approve integration or establish scientific superiority.

Maintainers LMMV/dprada own triage, without a response-time promise. Contributor/maintainer instructions explain category-specific procedure, labels and follow-up. Resource register provides navigation.